Page 57 - 2020_01-Haematologica-web

Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT
Bhagirathbhai Dholaria,1 Bipin N. Savani,1 Myriam Labopin,2 Leo Luznik,3 Annalisa Ruggeri,4 Stephan Mielke,5 Monzr M. Al Malki,6 Piyanuch Kongtim,7 Ephraim Fuchs,8 Xiao-Jun Huang,9 Franco Locatelli,10 Franco Aversa,11 Luca Castagna,12 Andrea Bacigalupo,13 Massimo Martelli,14 Didier Blaise,15 Patrick Ben Soussan,16 Yolande Arnault,17 Rupert Handgretinger,18 Denis-Claude Roy,19 Paul O’Donnell,20 Asad Bashey,21 Scott Solomon,21 Rizwan Romee,22 Philippe Lewalle,23 Jorge Gayoso,24 Michael Maschan,25 Hillard M. Lazarus,26 Karen Ballen,27 Sebastian Giebel,28 Frederic Baron,29 Fabio Ciceri,30 Jordi Esteve,31 Norbert-Claude Gorin,32 Alexandros Spyridonidis,33 Christoph Schmid,34 Stefan O. Ciurea,35 Arnon Nagler36 and Mohamad Mohty37
1Department of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN, USA: 2Department of Haematology and EBMT Paris study office / CEREST-TC, Saint Antoine Hospital, Paris, France; 3Department of Oncology Hematologic Malignancies, Johns Hopkins University School of Medicine, Baltimore, MD, USA; 4Department of Pediatric Hematology/Oncology and Cell and Gene Therapy, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy; 5Department of Laboratory Medicine, CAST, Karolinska Institutet and University Hospital, Stockholm, Sweden; 6Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA; 7Stem Cell Transplant and Cellular Therapy, Thammasat University, Pathumthani, Thailand; 8Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; 9Peking University People’s Hospital, Peking University Institute of Hematology, Beijing China; 10Department of Pediatric Hematology/Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Sapienza, University of Rome, Italy; 11Department of Medicine and Surgery, University of Parma, Parma, Italy; 12Instituto Clinico Humanitas, Rozzano Milano, Italy; 13Fondazione Policlinico Universitario Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy; 14University of Perugia, Sant'Andrea Delle Fratte, Perugia Italy; 15Department of Hematology, Institut Paoli Calmettes, Marseille France; 16Department of Clinical Psychology, Paoli-Calmettes Institute, Marseille, France; 17Institut Paoli-Calmette, département de psycholo- gie clinique, Marseille, France; 18Department of Hematology and Oncology, University Children's Hospital Tübingen, Tübingen Germany; 19Division of Hematology and Medical Oncology, Hospital Maisonneuve-Rosemont, Montreal, QC, Canada; 20Hematology-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; 21Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA; 22Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; 23Hematology Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; 24HGU Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; 25Oncology and immunology, Dmitriy Rogachev National Medical Center of pediatric hematology, Moscow, Russia; 26Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH, USA; 27Division of hematology/oncology, University of Virginia Health System, Charlottesville, VA, USA; 28Dept. of Bone Marrow Transplantation and Onco- Hematology, Maria Sklodowska-Curie Institute - Oncology Center, Gliwice Branch, Gliwice, Poland; 29Laboratory of Hematology, University of Liège, Liège, Belgium; 30Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milano Italy; 31Hematology department, Hospital Clínic de Barcelona, Barcelona Spain; 32Service d'hématologie et thérapie cellulaire Centre international greffes APHP-EBMT-INCa Hospital, Saint Antoine Hospital, Paris France; 33Bone Marrow Transplantation Unit and CBMDP Donor Center, University Hospital of Patras, Patras, Greece; 34Department of Hematology and Oncology, Klinikum Augsburg, Augsburg, Germany; 35Stem Cell Transplant and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 36Chaim Sheba Medical Center, Tel Aviv University, Tel-Hashomer, Israel and EBMT ALWP office, Saint Antoine Hospital , Paris, France and
Ferrata Storti Foundation
Haematologica 2020 Volume 105(1):47-58
37Service d’Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Sorobonne University, and INSERM UMRs 938, Paris, France
ABSTRACT
Donor lymphocyte infusion has been used in the management of relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. It can eradicate minimal residual disease or be used to rescue a hematologic relapse, being able to induce durable remis- sions in a subset of patients. With the increased use of haploidentical
Correspondence:
BHAGIRATHBHAI DHOLARIA
bhagirathbhai.r.dholaria@vumc.org
Received: February 17, 2019. Accepted: September 19, 2019. Pre-published: September 19, 2019.
doi:10.3324/haematol.2019.219790
Check the online version for the most updated information on this article, online supplements, and information on authorship & disclosures: www.haematologica.org/content/105/1/47
©2020 Ferrata Storti Foundation
Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or inter- nal use. Sharing published material for non-commercial pur- poses is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for com- mercial purposes is not allowed without permission in writing from the publisher.
haematologica | 2020; 105(1)
47
GUIDELINE ARTICLE